OncoMatch/Clinical Trials/NCT03964506
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
Is NCT03964506 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Hyperbaric oxygen for acute myeloid leukemia.
Treatment: Hyperbaric oxygen — The purpose of this study is to determine if hyperbaric oxygen therapy is safe in the setting of stem cell transplantation. This study will also determine if hyperbaric oxygen therapy improves engraftment, graft versus host disease, neutrophil count, and incidence and severity of mucositis (inflammation of the mouth or gut) and infection. This study has two cohorts. The first cohort is subjects with acute myeloid leukemia (AML) or Myelodysplastic Syndrome (MDS). The second cohort is subjects with chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), chronic monocytic leukemia, chronic neutrophilic leukemia (CNL), myelofibrosis, and myelodysplastic/myeloproliferative (MDS/MPN) overlap syndrome. The first cohort has completed the recruitment so only the second cohort will be recruited.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Chronic Myeloid Leukemia
Myeloproliferative Neoplasm
Prior therapy
Cannot have received: intrathecal chemotherapy
Patients who had intrathecal chemotherapy within 2 weeks of starting preparative regimen
Cannot have received: cranial irradiation
cranial irradiation within 4 weeks of starting preparative regimen
Lab requirements
Kidney function
serum creatinine: 2.0 mg/dL
Liver function
ALT, AST < 4x IULN and serum total bilirubin 2.0 mg/dL
Cardiac function
Left ventricular ejection fraction 45% measured by 2D-ECHO or MUGA scan; EKG with no clinically significant arrhythmia
Adequate hepatic, renal, cardiac and pulmonary function to be eligible for transplant. Minimum criteria include: Hepatic: ALT, AST < 4x IULN and serum total bilirubin 2.0 mg/dL; Renal: serum creatinine: 2.0 mg/dL; Left ventricular ejection fraction 45% measured by 2D-ECHO or MUGA scan; EKG with no clinically significant arrhythmia; FEV1, FVC and DLCO 50% of predicted value (corrected to serum hemoglobin)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Wilmot Cancer Institute, University of Rochester · Rochester, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify